Insulin: A critical autoantigen and potential therapeutic agent in type 1 diabetes

Expert Review of Clinical Immunology

Volumn 2, Issue 3, 2006, Pages 419-431

  Pugliese, Alberto ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; C PEPTIDE; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUTAMATE DECARBOXYLASE; HEAT SHOCK PROTEIN; HEMOGLOBIN A1C; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; INSULIN; INSULIN ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 4; PANCREAS ISLET CELL ANTIBODY; PEPTIDE HORMONE; PLACEBO; PROINSULIN; PROTEIN TYROSINE PHOSPHATASE; SULFONYLUREA;

ANTIBODY DETECTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CELL LOSS; CHROMOSOME 6; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC MANIPULATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KNOCKOUT MOUSE; LYMPHOCYTIC INFILTRATION; LYMPHOID TISSUE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; THYMUS; TRANSGENIC MOUSE; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 33748494687     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.3.419     Document Type: Review

References (106)

1. Turner R, Stratton I, Horton V et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in Type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350(9087), 1288-1293 (1997).
2. Steele C, Hagopian WA, Gitelman S et al. Insulin secretion in Type 1 diabetes. Diabetes 53(2), 426-433 (2004).
3. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained a cell apoptosis in patients with long-standing Type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 48(11), 2221-2228 (2005).
4. Pugliese A. Genetics of Type 1 diabetes. Endocrinol Metab. Clin. North Am. 33(1), 1-16, vii (2004).
5. Concannon P, Erlich HA, Juliet C et al. Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. Diabetes 54(10), 2995-3001 (2005)
6. Pugliese A. The insulin gene in Type 1 diabetes. IUBMB. Life 57(7), 463-468 (2005).
7. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2(7892), 1279-1283 (1974).
8. Gorsuch AN, Spencer KM, Lister J et al. Evidence for a long prediabetec period in Type I (insulin-dependent) diabetes mellitus. Lancet 2(8260-8261), 1363-1365 (1981).
9. Decochez K, Tits J, Coolens JL et al. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of Type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. Diabetes Care 23(6), 838-844 (2000).
10. Krischer JP, Cuthbertson DD, Yu L et al. Screening strategies for the identification of multiple antibody-positive relatives of individuals with Type 1 diabetes. J. Clin. Endocrinol. Metab. 88(1), 103-108 (2003).
11. Hampe CS, Hammerle LP, Bekris L et al. Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes. J. Clin. Endocrinol. Metab. 85(12), 4671-4679 (2000).
12. Serreze DV and Silveira PA. The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune Type 1 diabetes. Curr. Dir. Autoimmun. 6, 212-227 (2003).
13. Tree TI, Peakman M. Autoreactive T cells in human Type 1 diabetes. Endocrinol. Metab. Clin. North Am. 33(1), 113-133 (2004).
14. Foulis AK. The pathology of the endocrine pancreas in Type 1 (insulin-dependent) diabetes mellitus. APMIS 104(3), 161-167 (1996).
15. Rabinovitch A. Immunoregulation by cytokines in autoimmune diabetes. Adv. Exp. Med. Biol. 520, 159-193 (2003).
16. Lieberman SM, DiLorenzo TP. A comprehensive guide to antibody and T-cell responses in Type 1 diabetes. Tissue Antigens 62(5), 359-377 (2003).
17. George SK, Preda I, Avagyan S et al. Immunokinetics of autoreactive CD4 T cells in blood: a reporter for the "hit-and-run" autoimmune attack on pancreas and diabetes progression. J. Autoimmun. 23(2), 151-160 (2004).
18. Conrad B, Weidmann E, Trucco G et al. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 371(6495), 351-355 (1994).
19. Imagawa A, Hanafusa T, Tamura S et al. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in Type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes 50(6), 1269-1273 (2001).
20. Gianani R, Putnam A, Still T et al. Initial results of screening of non-diabetic organ donors for expression of islet autoantibodies. J. Clin. Endocrinol. Metab. (2006) (Epub ahead of print).
21. Pugliese A, Allende G, Laughlin E et al. Recurrence of autoantibodies and autoreactive T cells in patients with Type 1 diabetes following pancreas transplantation. Diabetes 53(Suppl. 2), A69 (2004).
22. Palmer JP, Asplin CM, Clemons P et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222(4630), 1337-1339 (1983).
23. Vardi P, Dib SA, Tuttleman M et al. Competitive insulin autoantibody assay. Prospective evaluation of subjects at high risk for development of type I diabetes mellitus. Diabetes 36(11), 1286-1291 (1987).
24. Vardi P, Ziegler AG, Mathews JH et al. Concentration of insulin autoantibodies at onset of type I diabetes. Inverse log-linear correlation with age. Diabetes Care 11(9), 736-739 (1988).
25. Ziegler R, Alper CA, Awdeh ZL et al. Specific association of HLA-DR4 with increased prevalence and level of insulin autoantibodiesin first-degree relatives of patients with type I diabetes. Diabetes 40(6), 709-714 (1991).
26. Pugliese A, Bugawan T, Moromisato R et al. Two subsets of HLA-DQA1 alleles mark phenotypic variation in levels of insulin autoantibodies in first degree relatives at risk for insulin-dependent diabetes. J. Clin. Invest. 93(6), 2447-2452 (1994).
27. Yu L, Rewers M, Gianani R et al. Antiislet autoantibodies usually develop sequentially rather than simultaneously. J. Clin. Endocrinol. Metab. 81(12), 4264-4267 (1996).
28. 1 dominated and suggest antigen-specific regulation. J. Immunol. 163(1), 525-532 (1999).
29. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with Type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48(3), 460-468 (1999).
30. Yu L, Robles DT, Abiru N et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc. Natl. Acad. Sci. USA 97(4), 1701-1706 (2000).
31. Colman PG, McNair P, Margetts H et al. The Melbourne Pre-Diabetes Study: prediction of Type 1 diabetes mellitus using antibody and metabolic testing. Med. J. Aust. 169(2), 81-84 (1998).
32. Achenbach P, Koczwara K, Knopff A et al. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to Type 1 diabetes. J. Clin. Invest. 114(4), 589-597 (2004).
33. Aoki CA, Borchers AT, Ridgway WM et al. NOD mice and autoimmunity. Med. J. Aust. 4(6), 373-379 (2005).
34. Trudeau JD, Kelly-Smith C, Verchere CB et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J. Clin. Invest. 111(2), 217-223 (2003).
35. Chen W, Bergerot I, Elliott JF et al. Evidence that a peptide spanning the B-C junction of proinsulin is an early autoantigen epitope in the pathogenesis of Type 1 diabetes. J. Immunol. 167(9), 4926-4935 (2001).
36. Daniel D, Gill RG, Schloot N, Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur. J. Immunol. 25, 1056-1062 (1995).
37. Wong FS, Karttunen J, Dumont C et al. Identification of an MHC class I-restricted autoantigen in Type 1 diabetes by screening an organ-specific cDNA library. Nature Med. 5(9), 1026-1031 (1999).
38. Liu E, Abiru N, Moriyama H, Miao D, Eisenbarth GS. Induction of insulin autoantibodies and protection from diabetes with subcutaneous insulin B:9-23 peptide without adjuvant. Ann. NY Acad. Sci. 958, 224-227 (2002).
39. Moriyama H, Wen L, Abiru N et al. Induction and acceleration of insulitis/diabetes in mice with a viral mimic (polyinosinic-polycytidylic acid) and an insulin self-peptide. Proc. Natl Acad. Sci. USA 99(8), 5539-5544 (2002).
40. Abiru N, Maniatis AK, Yu L et al. Peptide and major histocompatibility complex-specific breaking of humoral tolerance to native insulin with the B9-23 peptide in diabetes-prone and normal mice. Diabetes 50(6), 1274-1281 (2001).
41. Rudy G, Stone N, Harrison LC et al. Similar peptides from two β cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Mol. Med. 1(6), 625-633 (1995).
42. Durinovic-Bello I, Boehm BO, Ziegler AG. Predominantly recognized proinsulin T helper cell epitopes in individuals with and without islet cell autoimmunity. J. Autoimmun. 18(1), 55-66 (2002).
43. Narendran P, Williams AJ, Elsegood K, Leech NJ, Dayan CM. Humoral and cellular immune responses to proinsulin in adults with newly diagnosed Type 1 diabetes. Diabetes Metab. Res. Rev. 19(1), 52-59 (2003).
44. Alleva DG, Crowe PD, Jin L et al. A disease-associated cellular immune response in Type 1 diabetics to an immunodominant epitope of insulin. J. Clin. Invest. 107(2), 173-180 (2001).
45. Toma A, Haddouk S, Briand JP et al. Recognition of a subregion of human proinsulin by class I-restricted T cells in Type 1 diabetic patients. Proc. Natl Acad. Sci. USA 102(30), 10581-10586 (2005).
46. Hassainya Y, Garcia-Pons F, Kratzer R et al. Identification of naturally processed HLA-A2-restricted proinsulin epitopes by reverse immunology. Diabetes 54(7), 2053-2059 (2005).
47. Kent SC, Chen Y, Bregoli L et al. Expanded T cells from pancreatic lymph nodes of Type 1 diabetic subjects recognize an insulin epitope. Nature 435(7039), 224-228 (2005).
48. Mannering SI, Harrison LC, Williamson NA et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J. Exp. Med. 202(9), 1191-1197 (2005).
49. Solimena M. Vesicular autoantigens of Type 1 diabetes. Diabetes Metab. Rev. 14(3), 227-240 (1998).
50. Harashima S, Clark A, Christie MR, Notkins AL. The dense core transmembrane vesicle protein IA-2 is a regulator of vesicle number and insulin secretion. Proc. Natl Acad. Sci. USA 102(24), 8704-8709 (2005).
51. + T cells in human subjects. J. Immunol. 176(5), 2781-2789 (2006).
52. Araki E, Oyadomari S, Mori M. Impact of endoplasmic reticulum stress pathway on pancreatic β-cells and diabetes mellitus. Exp. Biol. Med. (Maywood) 228(10), 1213-1217 (2003).
53. Oyadomari S, Araki E, Mori M. Endoplasmic reticulum stress-mediated apoptosis in pancreatic β-cells. Apoptosis 7(4), 335-345 (2002).
54. Allen JR, Nguyen LX, Sargent KE et al. High ER stress in β-cells stimulates intracellular degradation of misfolded insulin. Biochemistry Biophysics Res. Commun. 324(1), 166-170 (2004).
55. Devaskar SU, Singh BS, Carnaghi LR, Rajakumar PA, Giddings SJ. Insulin II gene expression in rat central nervous system. Regulatory Peptides 48, 55-63 (1993).
56. Taha A, Budd GC, Pansky B. Preproinsulin messenger ribonucleic acid in the rat adrenal gland. Ann. Clin. Lab. Sci. 23(6), 469-476 (1993).
57. Budd GC, Pansky B, Glatzer L. Preproinsulin mRNA in the rat eye. Invest. Ophthalmol. Vis. Sci. 34(2), 463-469 (1993).
58. Giddings SJ, King CD, Harman KW, Flood JF, Carnaghi LR. Allele specific inactivation of insulin 1 and 2, in the mouse yolk, indicates imprinting. Nature Genetics 6, 310-313 (1994).
59. Kendzierski KS, Pansky B, Budd GC, Saffran M. Evidence for biosynthesis of preproinsulin in gut of rat. Endocrine 13(3), 353-359 (2000).
60. Pugliese A. Central and peripheral autoantigen presentation in immune tolerance. Immunology 111, 138-146 (2004).
61. Pugliese A, Brown D, Garza D et al. Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. J. Clin. Invest. 107(5), 555-564 (2001).
62. Diez J, Park Y, Zeller M et al. Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 Type 1 diabetes autoantigen. Diabetes 50(4), 895-900 (2001).
63. Garcia CA, Prabakar KR, Diez J et al. Dendritic cells in human thymus and periphery display a proinsulin epitope in a transcription-dependent, capture-independent fashion. J. Immunol. 175(4), 2111-2122 (2005).
64. Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199(2), 155-166 (2004).
65. Pugliese A, Zeller M, Fernandez AJ et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for Type 1 diabetes. Nat. Genetics 15(3), 293-297 (1997).
66. Vafiadis P, Bennett ST, Todd JA et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat. Genetics 15(3), 289-292 (1997).
67. Bennett ST, Todd JA. Human Type 1 diabetes and the insulin gene: principles of mapping polygenes. Annu. Rev. Genetics 30, 343-370 (1996).
68. Pugliese A, Zeller M, Fernandez A Jr et al. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for Type 1 diabetes. Nat. Genet. 15, 293-297 (1997).
69. Chentoufi AA, Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes 51(5), 1383-1390 (2002).
70. Brimnes MK, Jensen T, Jorgensen TN et al. Low expression of insulin in the thymus of non-obese diabetic mice. J. Autoimmun. 19(4), 203-213 (2002).
71. French MB, Allison J, Cram DS et al. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 46(1), 34-39 (1997).
72. Thebault-Baumont K, Dubois-Laforgue D, Krief P et al. Acceleration of Type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J. Clin. Invest. 111(6), 851-857 (2003).
73. Moriyama H, Abiru N, Paronen J et al. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc. Natl Acad. Sci. USA 100(18), 10376-10381 (2003).
74. Jaeckel E, Lipes MA, von Boehmer H. Recessive tolerance to preproinsulin 2 reduces but does not abolish Type 1 diabetes. Nat. Immunol. 5(10), 1028-1035 (2004).
75. Abiru N, Wegmann D, Kawasaki E et al. Dual overlapping peptides recognized by insulin peptide B:9-23 T cell receptor AV13S3 T cell clones of the NOD mouse. J. Autoimmun. 14(3), 231-237 (2000).
76. Nakayama M, Abiru N, Moriyama H et al. Prime role for an insulin epitope in the development of Type 1 diabetes in NOD mice. Nature 435(7039), 220-223 (2005).
77. Nakayama M, Babaya N, Miao D et al. Thymic expression of mutated B16:A preproinsulin messenger RNA does not reverse acceleration of NOD diabetes associated with insulin 2 (thymic expressed insulin) knockout. J. Autoimmun. 25(3), 193-198 (2005).
78. Dogra RS, Vaidyanathan P, Prabakar KR et al. Alternative splicing of G6PC2, the gene coding for the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), results in differential expression in human thymus and spleen compared with pancreas. Diabetologia (2006) (Epub).
79. Kralovicova J, Gaunt TR, Rodriguez S et al. Variants in the human insulin gene that affect pre-mRNA splicing: is -23HphI a functional single nucleotide polymorphism at IDDM2? Diabetes 55(1), 260-264 (2006).
80. Kubosaki A, Miura J, Notkins AL. IA-2 is not required for the development of diabetes in NOD mice. Diabetologia 47(1), 149-150 (2004).
81. Jaeckel E, Klein L, Martin-Orozco N, von Boehmer H. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. J. Exp. Med. 197(12), 1635-1644 (2003).
82. Geng L, Solimena M, Flavell RA, Sherwin RS, Hayday AC. Widespread expression of an autoantigen-GAD65 transgene does not tolerize non-obese diabetic mice and can exacerbate disease. Proc. Natl Acad. Sci. USA 95(17), 10055-10060 (1998).
83. Kash SF, Condie BG, Baekkeskov S. Glutamate decarboxylase and GABA in pancreatic islets: lessons from knock-out mice. Horm. Metab. Res. 31(5), 340-344 (1999).
84. Muir A, Schatz D, Maclaren N. Antigen-specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabetes Metab. Rev. 9(4), 279-287 (1993).
85. + T cells that suppress adoptive transfer of diabetes. J Autoimmun. 7(5), 655-663 (1994).
86. Maron R, Guerau-de-Arellano M, Zhang X, Weiner HL. Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. J. Autoimmun. 16(1), 21-28 (2001).
87. Atkinson M, Maclaren N, Luchetta R, Burr I. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39, 933-937 (1990).
88. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes. J. Exp. Med. 184(6), 2167-2174 (1996).
89. Martinez NR, Augstein P, Moustakas AK et al. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J. Clin. Invest. 111(9), 1365-1371 (2003).
90. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl Acad. Sci. USA 93(2), 956-960 (1996).
91. Alleva DG, Gaur A, Jin L et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant Type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 51(7), 2126-2134 (2002).
92. Liu E, Moriyama H, Abiru N et al. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J. Clin. Invest. 110(7), 1021-1027 (2002).
93. Pedotti R, Sanna M, Tsai M et al. Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune Type 1 diabetes mellitus. BMC. Immunol. 4(1), 2 (2003).
94. Hanninen A, Braakhuis A, Heath WR, Harrison LC. Mucosal antigen primes diabetogenic cytotoxic T-lymphocytes regardless of dose or delivery route. Diabetes 50(4), 771-775 (2001).
95. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 341(8850), 927-928 (1993).
96. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with Type 1 diabetes mellitus. N. Engl. J. Med. 346(22), 1685-1691 (2002).
97. Karounos DG, Goes SU, Bryson JS. Dose of insulin is a critical factor in the prevention of Type 1 diabetes in NOD mice. Diabetes 52(Suppl. 1), A276 (2003).
98. Skyler JS, Krischer JP, Wolfsdorf J et al. Effects of oral insulin in relatives of patients with Type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 28(5), 1068-1076 (2005).
99. Faria AM and Weiner HL. Oral tolerance. Immunol. Rev. 206, 232-259 (2005).
100. Maruyama T, Shimada A, Kanatsuka A et al. Multicenter prevention trial of slowly progressive Type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann. NY Acad. Sci. 1005, 362-369 (2003).
101. Hanninen A and Harrison LC. γδ T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol. Rev. 173, 109-119 (2000).
102. Harrison LC, Honeyman MC, Steele CE et al. Pancreatic β-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for Type 1 diabetes. Diabetes Care 27(10), 2348-2355 (2004).
103. Alleva DG, Maki RA, Putnam AL et al. Immunomodulation in Type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand. J. Immunol. 63(1), 59-69 (2006).
104. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N. Engl. J. Med. 346(22), 1692-1698 (2002).
105. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med. 352(25), 2598-2608 (2005).
106. Raz I, Elias D, Avron A et al. β-cell function in new-onset Type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, Phase II trial. Lancet 358(9295), 1749-1753 (2001).